Michaela Zoi Psarommati

Ms. Michaela Zoi Psarommati


Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 September 2023 in Cancers
Verified
Journal Article
Open access
PDF file
ZFZacharias Fasoulakis
Zacharias Fasoulakis
MPMichaela Zoi Psarommati
Michaela Zoi Psarommati
APAngeliki Athanasios Papapanagiotou
Angeliki Athanasios Papapanagiotou
Vasilios PergialiotisVasilios Pergialiotis
Vasilios Pergialiotis
AKAntonios Koutras
Antonios Koutras
Panos AntsaklisPanos Antsaklis
Panos Antsaklis
Ovarian cancer is a deadly disease that affects thousands of women worldwide. Integrins, transmembrane receptors that mediate cell adhesion and signaling, play important roles in ovarian cancer progression, metastasis, and drug resistance. Dysregulated expression of integrins is implicated in various cellular processes, such as cell migration, invasion, and proliferation. Emerging evidence suggests that microRNAs (miRNAs) can regulate integrin expression and function, thus affecting various physiological and pathological processes, including ovarian cancer. In this article, we review the current understanding of integrin-mediated cellular processes in ovarian cancer and the roles of miRNAs in regulating integrins. We also discuss the therapeutic potential of targeting miRNAs that regulate integrins for the treatment of ovarian cancer. Targeting miRNAs that regulate integrins or downstream signaling pathways of integrins may provide novel therapeutic strategies for inhibiting integrin-mediated ovarian cancer progression.